Intravenous immunoglobulins: a treatment for Alzheimer's disease?

Alzheimers Disease: Review of Emerging Treatment Role for Intravenous Immunoglobulins

Alzheimer's disease (AD) is the most common neurodegenerative disorder. Currently available therapies are symptomatic but do not alter underlying disease progression. Immunotherapeutic approaches such as anti Aβ peptide active vaccination trials have had limited success to date. Intravenous immunoblobulin (IVIg) is widely used in immune-mediated neurological disorders such myasthenia gravis and...

Autoimmune neuropathies and treatment with intravenous immunoglobulins

Glucose Role in Treatment of Alzheimers’ Disease

1. Dong H, Csernansky JG (2009) Effects of Stress and Stress Hormones on Amyloidβ Protein and Plaque Deposition. J Alzheimers Dis 18: 459-469. 2. Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, et al. (2006) Plasma cortisol and progression of dementia in subjects with Alzheimer‐ type dementia. Am J Psychiatry 163: 2164-2169. 3. Swaab DF, Raadsheer FC, Endert E, Hofman MA, Kamphorst W, et al. ...

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease.

OBJECTIVE Active or passive immunisation can mitigate plaque pathology in murine models of Alzheimer's disease (AD). Recently, it has been shown that antibodies against beta-amyloid (Abeta) are present in human immunoglobulin preparations (IVIgG), which specifically recognise and inhibit the neurotoxic effects of Abeta. This study reports the results from a pilot study using IVIgG in patients w...

Intravenous immunoglobulins containing antibodies against b-amyloid for the treatment of Alzheimer’s disease

R C Dodel, Y Du, C Depboylu, H Hampel, L Frölich, A Haag, U Hemmeter, S Paulsen, S J Teipel, S Brettschneider, A Spottke, C Nölker, H J Möller, X Wei, M Farlow, N Sommer, W H Oertel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ....